MENU
AUG 29, 2019 8:00 AM PDT

Implementation of Helicobacter Pylori Stool Antigen Testing in a Large Metropolitan Center: A Prospective Comparative Diagnostic Trial

Sponsored by: DiaSorin
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor of Pathology and Laboratory Medicine and Medicine at the University of Calgary
    Biography
      Dr. Pillai is a Professor of Pathology and Laboratory Medicine and Medicine at the University of Calgary, and practices in both Medical Microbiology and Infectious Diseases. His research interest comprises translational studies related to improving cost-effectiveness and outcomes from the implementation of new diagnostic algorithms. A particular focus has been on point-of-care and near-patient diagnostics both at home and in resource-limited settings in order to reduce disparities. He has published close to 100 peer-reviewed articles, obtained over $1.5M in direct peer-reviewed funding and $6M as co-investigator over the last 10 years. He has trained several undergraduate, graduate, and post-doctoral scientists as well as clinical fellows. Dr. Pillai is a member of the College of American Pathologists Microbiology Committee, IDSA diagnostics committee, AMMI Canada Research and Grants Chair, and sits on several editorial boards related to Microbiology and Infectious Diseases.

    Abstract

    DATE: August 29, 2019
    TIME: 8:00am PDT, 11:00am EDT

    Background: Clinical guidelines for H. pylori screening and post-treatment testing endorse the use of urea breath test (UBT), H. pylori stool antigen test (HpSAT), and biopsy-related tests. Due to protracted wait times at our patient service centers and non-compliance in children and elderly with complications for the UBT, we sought to compare UBT and HpSAT in the city of Calgary, Canada with a population close to 1.4 million people.

    Methods: To achieve this, a prospective diagnostic trial was performed comparing UBT to HpSAT in patients presenting with dyspepsia. A total of N=150 patients agreed to undergo UBT (13C-UBT kit, Helikit, Isodiagnostika Inc.) and consented to provide a stool specimen for simultaneous HpSAT testing (Diasorin LIAISON® XL H. pylori SA Monoclonal chemiluminescent immunoassay) in our centralized laboratory.

    Results: Our data show that concordant results were obtained in 148/150 (98.7%) patients with a positivity rate of 18%. One of two discrepants (UBT positive/HpSAT negative) resolved after repeat testing. Using UBT as the gold standard, HpSAT had a sensitivity of 96.30% (95% CI; 81.03% to 99.91%) and specificity of 100% (95% CI; 97.05% to 100.00%). A positive predictive value of 100% and negative predictive value of 99.2% (95% CI; 94.73% to 99.88%) was obtained. For patients where drug information was available, 38/130 (29.2%) had received an antibiotic associated with H.pylori in the preceding 12 months, with UBT and HpSAT providing concordant results in 37/38 (97.4%) of these individuals. Of note, 6/130 (4.6%) patients had received a specific combination anti-H.pylori treatment, and all 6/6 (100%) had concordant negative results suggesting successful eradication. A post-implementation economic evaluation of labor and materials associated with testing demonstrates a cost-savings of approximately USD 5.47 per specimen in this locale.

    Conclusion: Our study confirms that HpSAT is a viable alternative to UBT for H. pylori screening in our jurisdiction with equivalent test performance and cost-savings. Pre- and post-implementation analysis of test compliance rates, waiting times, and test turn around times will also be presented.

    Learning Objectives:

    • Gain understanding of H.pylori testing options
    • Understand challenges and benefits of utilizing  H.pylori stool antigen testing
    • Gain skills to effectively manage key clinician stakeholders

     

     

    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    AUG 29, 2019 8:00 AM PDT

    Implementation of Helicobacter Pylori Stool Antigen Testing in a Large Metropolitan Center: A Prospective Comparative Diagnostic Trial

    Sponsored by: DiaSorin
    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Microbiology

    Laboratory Testing

    Infectious Disease

    Immunology

    Clinical Diagnostics

    Molecular Diagnostics

    Molecular Biology

    Clinical Chemistry

    Biotechnology

    Diagnostics

    Biochemistry

    Clinical Research

    Genetics

    Pcr/rt-Pcr/real-Time Pcr

    Cancer Research

    Geography

    North America78%

    Asia10%

    Europe7%

    South America2%

    Africa2%

    Oceania1%

    Registration Source

    Website Visitors54%

    Email Promotions34%

    WAVE Newsletter Promotion7%

    Social Media Promotions1%

    Client/Sponsor Promotions1%

    Trending Newsletter Promotion1%

    Other2%

    Job Title

    Medical Laboratory Technician25%

    Facility/Department Manager14%

    Lab Management13%

    Clinical Laboratory Scientist12%

    Executive9%

    Educator/Faculty5%

    Medical Doctor/Specialist4%

    Research Scientist4%

    Microbiologist3%

    Student3%

    Marketing/Sales3%

    QC/QA2%

    Scientist1%

    Consultant1%

    Chemist1%

    Organization

    Hospital28%

    Clinical Laboratory19%

    Academic Institution10%

    Medical Center5%

    Biotech Company4%

    Government4%

    Medical Device Company4%

    Diagnostic Company3%

    Research Institute2%

    Consultant2%

    General Laboratory2%

    Medical School1%

    Life Science Company1%

    Industrial Company1%

    Other4%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more